TP53 and colorectal cancer: Recent studies of the selective HDAC6 inhibitor A452 tested in colorectal cancer cell lines, demonstrated to affect p53 and HSP-90, increasing the level of wild-type p53 as a result of the destabilization of MDM2, but decreasing mutant p53 and the consequent inhibition of Hsp90-mutant p53 complex formation.